Allergan weakness an overreaction & a buying opportunity, says RBC Capital linked.
Allergan weakness a buying opportunity, says RBC Capital
Fly On the Wall 5/1/13
RBC Capital believes weakness in Allergan related to DARPin is an overreaction an would be a buyer on weakness. The firm believes weakness ignores strong upside drivers and reiterates its Outperform rating.